The cumulative incidence of grade @-@ acute graft-versus-host disease was @ % ( @ % CI @-@ ) in the rituximab group and @ % ( @ % CI @-@ ) in the no rituximab group ( hazard ratio -LSB- HR -RSB- @ , @ % CI @-@ ; p = @ ) .